SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trialsFaı̈ez Zannad, Milton Packer, Gerasimos Filippatos et al.|The Lancet|2020Cited by 1.4k
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney FunctionFaı̈ez Zannad, Milton Packer, Stefan D. Anker et al.|Circulation|2020Cited by 276